| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | ticagrelor (Brilique®) |
| Formulation | 90 mg dispersible tablet |
| Reference number | 3480 |
| Indication | Co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 07/04/2017 |